All Stories

  1. The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function
  2. Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-λ-1a and PEG-IFN-α2a in naive patients
  3. Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects
  4. Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables
  5. Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates
  6. Measuring biotherapeutics with endogenous counterparts and pre-existing antibodies: an interferon case study
  7. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects
  8. Determination of trimethoprim in low-volume human plasma by liquid chromatography
  9. Simplified method for determination of rosiglitazone in human plasma